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Skeletal muscle atrophy can result from a range of physiological conditions, including denervation, 
immobilization, hindlimb unweighting, and aging. To better characterize the molecular genetic 
events of atrophy, a microarray was performed using skeletal muscle isolated from mice after 3 
and 14 days of denervation and compared to control muscle to identify novel atrophy-induced 
genes. The microarray revealed that FGGY carbohydrate kinase domain containing (Fggy) is 
expressed in skeletal muscle and is induced in response to denervation. Bioinformatic analysis of 
the Fggy gene locus revealed two validated alternative isoforms, that we have termed Fggy-L-552 
and Fggy-S-387, which have distinct transcription initiation sites. In order to confirm that Fggy is 
expressed in muscle, the cDNAs of the two validated alternative variants were cloned from 
myoblast cells. Interestingly, two novel alternative splice variants, designated Fggy-L-482 and 
Fggy-S-344, were also cloned, suggesting that at least four Fggy splice variants are expressed in 
skeletal muscle. Quantitative RT-PCR (RT-qPCR) was performed using RNA isolated from 
muscle cells and primers designed to distinguish the four alternative Fggy transcripts. The RT-
qPCR data reveals that the Fggy-L transcripts are more highly expressed during myoblast 
differentiation, while the Fggy-S transcripts show relatively stable expression in proliferating 
myoblasts and differentiated myotubes. Confocal fluorescent microscopy revealed that the Fggy-
L variants appear to localize evenly throughout the cytoplasm, while the Fggy-S variants produce 
a more punctuate localization pattern throughout the cytoplasm of proliferating muscle cells. 
Finally, ectopic expression of Fggy-L-552 and Fggy-S-387 resulted in inhibition of muscle cell 
differentiation and attenuation of the MAP kinase and AKT signaling pathways. The 
characterization of novel genes induced during neurogenic atrophy helps improve our 
understanding of the molecular and cellular events that lead to muscle atrophy and may eventually 




Chapter 1: Skeletal Muscle Atrophy, MuRF1, and Muscle Cell Signaling 
Skeletal Muscle Atrophy  
Skeletal muscle atrophy is a decrease in the total muscle mass due to the rate of protein degradation 
outpacing the rate of protein synthesis (Bodine and Baehr, 2014). This change can be caused by a 
variety of physiological conditions, including aging, neuronal injury, disuse, and corticosteroid 
treatment (Bodine and Baehr, 2014). Atrophy is not specific to one disease, has many levels of 
severity, and is multifactorial, suggesting there may not be one simple way to prevent muscle 
wasting. However, having clearer insight into how the body regulates muscle atrophy may provide 
important information for the identification and development of new therapeutic targets to prevent 
this process.  
MuRF1 and MAFbx 
To explore atrophy at the molecular level, a study using rats undergoing muscle atrophy identified 
two E3 ubiquitin ligases named Muscle RING Finger 1 (MuRF1) and Muscle Atrophy F-Box 
(MAFbx) as being upregulated in virtually all atrophy models, including denervation, 
immobilization, unweighing, and treatment with interleukin-1 (IL-1) or dexamethasone (Bodine 
et al, 2001). A number of genes were observed to have differential expression under one or two 
conditions but only MuRF1 and MAFbx were found to be upregulated under all conditions (Fig. 
1). This study also showed that MuRF1 and MAFbx null mice are resistant to skeletal muscle 
atrophy (Bodine et al, 2001). After transection of the sciatic nerve, MuRF1 knockout mice showed 
36% muscle sparing at 14 days of denervation, while MAFbx knockout mice showed 56% sparing 
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at 14 days post denervation (Bodine et al, 2001). These findings demonstrated that MuRF1 and 
MAFbx are likely involved in a common atrophy cascade. Moreover, MuRF1 and MAFbx are 
known E3 ubiquitin ligases, and believed to participate in muscle atrophy by targeting substrate 
proteins for degradation via the ubiquitin proteasome pathway. 
 
Figure 1. MuRF1 and MAFbx are upregulated during muscle atrophy. Northern blot analysis 
of MuRF1 and MAFbx in muscle isolated from rats subjected to atrophy induction by 
immobilization, denervation, and hind limb suspension. Increased expression of MuRF1 and 
MAFbx was observed at day 1 and reached a peak at day 3 post-denervation (Bodine et al, 2001). 
 
The Ubiquitin Proteasome System  
Ubiquitin is a small, abundant protein that covalently attaches to target proteins, which frequently 
leads to degradation by the 26S proteasome (Borlepawar et al, 2018). Prior to attachment to target 
proteins, ubiquitin must first be activated by an E1 ubiquitin activating enzyme. The activated 
ubiquitin then binds to an E2 ubiquitin conjugating enzyme, which transfers the ubiquitin to the 
targeted protein with the E3 ligating enzyme serving as a platform to bring the E2 and substrate 
protein into proximity (Fig. 2). Protein degradation via the Ubiquitin Proteasome System (UPS) is 
very specific and although there are only two E1 enzymes (Jin et al., 2007) and about 40 E2 
enzymes (Stewart et al., 2016), there are around 600 different E3 enzymes that provide substrate 
specificity and allow this system to act in a precise manner (Mearini et al., 2008). UPS activity has 
been characterized under multiple physiological conditions that lead to muscle loss, including 
3 
denervation (Medina, Wing, and Goldberg, 1995), disuse (Taillander et al, 1996), and cancer 
cachexia (Temparis et al, 1994;Baracos, 1995).  
 
 
Figure 2. Schematic of the ubiquitin proteasome system. The E1 ubiquitin activating enzyme, 
E2 ubiquitin conjugating enzyme, and E3 ubiquitin ligase form a pathway to ubiquitinate 
substrates for degradation by the 26s proteasome (Dodd, 2011).  
 
MuRF1 as a Putative Transcriptional Regulator  
MuRF1 is a member of the tripartite motif (TRIM) family of E3 ubiquitin ligases that are 
characterized by a RING domain, a zinc-finger B-box domain, and a leucine-rich coiled-coil 
domain (Bodine and Baehr, 2014). The RING domain of E3 ubiquitin ligases functions by bringing 
substrate proteins and activated ubiquitin from the E2 into direct contact. The RING domain is 
believed to perform the catalytic activity of MuRF1, while the zinc-finger B-box domain is 
suggested to function in binding to target proteins (Ikeda et al, 2013).  
Although there are many studies focusing on its role in the UPS, there are other studies indicating 
MuRF1 may have an additional role as a transcriptional modulator (Furlow et al, 2013). One study 
suggests that MuRF1 may serve as a negative transcriptional regulator of itself and of MAFbx, but 
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it is unclear if this regulation is direct or indirect (Furlow et al, 2013). To investigate MuRF1 
further, a MuRF1 knockout mouse was created by inserting a β-galactosidase lacZ cassette into 
the MuRF1 locus, putting the β-galactosidase gene under the control of the endogenous MuRF1 
promoter and creating a MuRF1 reporter gene within the mouse genome (Bodine et al, 2001). 
When analyzing MuRF1 expression in denervated muscles from wild type mice, it was found that 
MuRF1 levels increase by 3 days of denervation but return to baseline by 14 days of denervation 
(Furlow et al, 2013). In contrast, MuRF1 gene locus activity does not return to baseline in the 
MuRF1-null mice as measured by β-galactosidase expression in the KO mice, suggesting that lack 
of MuRF1 leads to a failure to inhibit the MuRF1 promoter (Fig. 3A-B). Furthermore, this same 
study also showed that mice lacking MuRF1 failed to down regulate MAFbx expression after 14 
days of denervation (Fig. 3C-D). Finally, the microarray study revealed that MuRF1 KO leads to 
differential expression of a number of other genes in response to denervation including a gene 






Figure 3. Transcriptional activity of the MuRF1 gene locus and MAFbx in WT and MuRF1 
KO mice post-denervation. (A) Denervated WT mice show an increase in MuRF1 gene 
expression at day 3 (3D) but returns to baseline at day 14 (14D) post-denervation. (B) Denervated 
KO mice show an increase in β-galactosidase expression, which is under the control of the MuRF1 
promoter, at day 3 and expression remained elevated at day 14 post-denervation. (C) Denervated 
WT mice show an increase in MAFbx gene expression at day 3 (3D) but a return to baseline levels 
by day 14 (14D) post-denervation. (D) Denervated MuRF1 KO mice showed increased expression 
in MAFbx at day 3 (3D) that remained elevated at day 14 (14D) (Furlow et al, 2013). 
 
 
Mitogen-activated protein kinase signaling 
 
MAPK signaling is essential for the expression of muscle specific genes, muscle growth, and 
differentiation of muscle cells (Fig. 4) (Bennett and Tonks, 1997). It has previously been shown 
that MAPK signaling is critical for muscle cell differentiation, specifically complete differentiation 
and fusion of myoblasts into myotubes (Bennett and Tonks, 1997). The four branches of the MAP 
kinase signaling pathway include extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun 
amino-terminal kinase (JNK), p38, and ERK5 (Bennett et al, 1997). Moreover, the ERK1/2 branch 
has been linked to the regulation of skeletal muscle cell growth and differentiation (Bennett and 
Tonks, 1997). Specifically, the inactivation of this branch has been found to promote myogenesis 
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initiation (Adi et al, 2002; Bennett and Tonks, 1997) by leading to the upregulation of 
differentiation factors specific to skeletal muscle cell differentiation, including myogenin (Penna 
et al, 2010). Previous work from our lab has identified a number of genes that are differentially 
expressed in the MuRF1 KO model in response to denervation that are also linked to MAPK 
signaling. For example, Dual-specificity phosphatase 29 (Dusp29) and Dual-specificity 
phosphatase 4 (Dusp4), which are part of a large group of phosphatases that regulate the MAPK 
pathway (Caunt et al., 2012), have been shown to decrease the activity of the ERK1/2 branch 
(Cooper et al., 2020; Haddock et al., 2019). Further, Tetratricopeptide repeat domain containing 
39C (Ttc39c) and Family with sequence similarity 83 Member D (Fam83D), which are two 
putative scaffolding proteins important for modulating proper muscle cell signaling pathways, 
including the ERK1/2 branch of the MAP kinase signaling cascade, have been found to be 
differentially regulated in MuRF1 KO mice following denervation (Hayes et al., 2019; Cooper et 
al., 2020). Additionally, protein phosphatase methylesterase (Ppme1) has been found to regulate 
the MAPK signaling pathway through the ERK1/2 branch of MAP kinase signaling and inhibition 
of Ppme1 led to a decrease in whole ERK1/2 expression, as well as ERK1/2 phosphorylation levels 
(Labuzan et al., 2020).  
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Figure 4. Schematic of the MAPK signaling pathways (Wang, Xia, 2012). 
 
AKT signaling cascade 
In addition to MAPK signaling, AKT signaling is also known to be involved in the modulation of 
skeletal muscle mass (Hitachi and Tsuchida, 2014). The upstream regulator of AKT and mTOR, 
insulin-like growth factor-1 (IGF-1), is responsible in part for the induction of protein synthesis 
(Fig. 5) (Hitachi and Tsuchida, 2014). IGF-1 inhibits muscle atrophy and promotes muscle 
hypertrophy by activation of the AKT signaling pathway, which is known to promote protein 
synthesis in three ways; 1) by inhibition of GSK-3β, 2) by inhibition of the FoxO family of 
transcription factors, and 3) by activation of the mTOR pathway (Hitachi and Tsuchida, 2014). 
Glycogen synthase kinase 3 β (GSK-3β) is constitutively active and functions by inhibiting protein 
synthesis (MacAulay and Woodgett, 2008). Activated AKT phosphorylates GSK-3β to inactivate 
it, which allows its target proteins to become dephosphorylated (MacAulay and Woodgett, 2008). 
Forkhead box O (FoxO) is a family of transcription factors that activate the transcription of MuRF1 
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and MAFbx and promote muscle atrophy (Sandri et al., 2004). AKT phosphorylation of FoxO 
transcription factors inhibits their translocation into the nucleus and ability to activate atrophy 
promoting genes (Sandri et al., 2004). The activation of mTOR by AKT allows it to phosphorylate 
4E-BP1 which prevents it from binding and inactivating the initiation factor eIF4E, which leads to 
the release of eIF4E and a concomitant increase in protein translation levels within the muscle cell 
(Alessi et al., 1996; Tsai et al., 2015). Overall, the activation of the AKT signaling cascade results 
in a decrease in protein degradation via FoxO inactivation and an attenuation of MuRF1 and 
MAFbx activation. Moreover, AKT activation also leads to an increase in protein synthesis via 
GSK-3β inhibition and mTOR activation, which promotes muscle hypertrophy.  
 







Chapter 2: Identification and characterization of Fggy carbohydrate kinase domain 
containing in skeletal muscle 
Introduction 
The FGGY Carbohydrate Kinase Family 
The Fggy gene belongs to an evolutionarily related family of carbohydrate kinases that have been 
found to phosphorylate an array of various sugar substrates (Zhang et al., 2011). The Fggy 
carbohydrate kinase family includes, L-fucolokinase, gluconokinase, glycerol kinase, D-ribulose 
kinase, and L-xylulose kinase (Omelchenko et al., 2010). Of these, the glycerol kinases are the 
most widely conserved between the three domains of life (Fig. 6).  
 




The FGGY kinase family also consists of a subgroup, similar to the xylulose kinase, that 
phosphorylates autoinducer-2 (AI-2). AI-2 is a bacterial signaling molecule that plays a role in 
regulating bacterial behaviors such as cell to cell communication, biofilm formation, and gene 
expression (Xavier et al., 2007; Vendeville et al., 2005). Additionally, the rate of AI-2 synthesis 
and uptake has been shown to be elevated in the presence of glucose (Wang et al., 2005). Although 
characterization of the functional role of this diverse family of kinases remains ongoing, it is 
known that they possess two conserved domains referred to as the N-terminal (FGGY-N) and C-
terminal (FGGY-C) (Hurley et al., 1996; Hurley et al., 1993). The two domains both adopt a 
ribonuclease H-like fold and the cleft formed between the two domains acts as the binding site for 
substrates, as well as ATP (Hurley et al., 1993). 
Fggy carbohydrate kinase domain-containing 
The Fggy carbohydrate kinase domain-containing gene (Fggy) encodes a protein with at least 90% 
conservation between humans, mice, and rats (Madiera et al., 2019). In humans, it is found on the 
short arm of the first chromosome and in mice it is found on the fourth chromosome.  
A previous study in HEK293 cells found that Fggy may function in the pentose phosphate pathway 
(also known as the phosphogluconate pathway or hexose monophosphate shunt) and is a metabolic 
pathway that runs parallel to glycolysis, but appears to play a primary role in the generation of 
precursors for the synthesis of nucleotides (Fig. 7) (Singh et al., 2017; Ge et al., 2020). Fggy has 
previously been suggested to be associated with sporadic amyotrophic lateral sclerosis (S-ALS) 
(Dunckley et al., 2007), but further studies have failed to corroborate these results which might be 
due to the complexity of this multifactorial disease (Doud et al., 2012 and Cai et al., 2014). 
Although previous studies have not generated a consensus regarding a role for Fggy in S-ALS 
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development of progression, it is an intriguing possibility since we identified Fggy as a novel 
neurogenic atrophy-induced gene in skeletal muscle.  
 
Figure 7. Schematic of the pentose phosphate pathway (PPP). Enzymes in the oxidative and 
non-oxidative PPP are shaded in green (Ge et al., 2020). 
 
   In addition to a putative role in skeletal muscle, Fggy has also been identified as a tumor 
suppressor gene and as a potential biomarker for the severity of lung squamous cell carcinoma 
(LUSC) due to an observed negative relationship between the expression of a Fggy mutant isoform 
and LUSC prognosis (Zhang et al., 2019). Specifically, poor LUSC clinical outcomes have been 
linked to a specific mutant variant of the Fggy gene designated LINE-1-FGGY (L1-FGGY). L1-
FGGY is generated when a transposon, called the long-interspersed element 1 (LINE-1), is inserted 
into the beginning of the thirteenth exon of Fggy via retro-transposition which inactivates the Fggy 
gene (Zhang et al 2019). Inactivation of the Fggy gene resulted in increased cell proliferation and 
dysregulation of cell energy metabolism further suggesting a role of Fggy in energy metabolism 
and identifying a new role for Fggy in regulating cell proliferation (Zhang et al 2019). Finally, in 
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adipose tissue, a low dose of bisphenol A (BPA) exposure in fetal mice decreased the instance of 
hypermethylation of the Fggy promoter which lead to an increase in Fggy transcription (Taylor et 
al., 2018). As a result, an increase in the amount of adipose tissue and diet induced obesity in adult 
mice was observed (Taylor et al., 2018). Previous studies linking Fggy to cell metabolism, adipose 
tissue development, and regulation of cell proliferation provide intriguing insights into the 
potential functional role that Fggy may play in the molecular mechanisms of skeletal muscle 
atrophy. Here, we present the first investigation of the role that Fggy plays in skeletal muscle. 
 
Materials and Methods 
Animals  
There were no animal experiments related to the current study conducted at the University of North 
Florida; however, the sex, age range, strain, and treatment conditions of the animals used for the 
Illumina array studies, as well as the IUCAC approvals, have been previously described (Furlow 
et al., 2013) 
Cell Culture 
C2C12 mouse myoblasts were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Thermo Fischer Scientific, Waltham, MA) supplemented with 1X Penicillin/Streptomycin and 
Gentamicin (Thermo Fischer Scientific, Waltham, MA), non-essential amino acids (GE 
Healthcare HyClone Laboratories, Logan, UT), and 10% Fetal Bovine Serum (FBS) (GE 
Healthcare HyClone Laboratories, Logan, UT). Cells were grown in a humidified chamber at 37° 
C and 5% CO2. DMEM with 2% FBS, Penicillin/Streptomycin and Gentamicin, and non-essential 
amino acids was used to induce C2C12 myoblast differentiation when cells reached 100% 
confluency. 
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RNA isolation and complementary DNA synthesis 
Total RNA was isolated from C2C12 cells using the RNeasy Mini Kit (Qiagen, Valencia, CA) and 
following the manufacturer’s instructions. Isolated RNA was used to synthesize complementary 
DNA (cDNA) using a PolyT primer and Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase (Thermo Fisher Scientific, Waltham, MA) and following the manufacturer’s 
instructions.  
Cloning of the Fggy cDNA  
Gene specific primers (Table 1) were designed using the gene sequences for murine Fggy-L 
(GenBank accession number: NM_001113412.1) and Fggy-S (GenBank accession number: 
NM_029347.2) and mixed with template DNA generated by reverse transcription as described 
above, and Taq polymerase. PCR reactions were performed by following the manufacturer’s 
protocol (Life Technologies, Grand Island, NY).  
Fggy open reading frames (ORFs) were cloned into the pGEM-T Easy vector using the 
manufacturer’s provided protocol (Promega, Madison, WI) and sequenced to confirm the absence 
of mutations using the Big Dye Sanger terminator sequencing method (Eurofins MWG Operon, 
Huntsville, AL). Fggy ORFs were sub-cloned into the HindIII and BamHI restriction sites of the 
pcDNA3.1 1(+) (ThermoFisher Scientific, Waltham, MA) and pEGFP-C3 (Clontech, Mountain 







Table 1. Primer Sequences (5’ to 3’)  
Primer Name Sequence 
Fggy-cDNA3-L-552-F GCAAGCTTACCATGATGTCTGGCAGAGACCAGG 
Fggy-cDNA3- L-552-R GCGGATCCGGACAGGTATGTTCAGCTTCCATTCATG 
Fggy-cDNA3-S-387-F GCAAGCTTACCATGATGTCTGGCAGAGACCAGG 
Fggy-cDNA3- S-387-R GCGGATCCGCATTCTTAAAATGCTTTAGAAGAAG 
Fggy-L-482-qPCR-F AGATCCAGTGTTTGTACCAGG 
Fggy-L-482-qPCR-R CCAGTGACCAATTTTCCAGTC 
Fggy- L-552-qPCR-F ATGGCAACCGGTCTCCCTTAG 
Fggy- L-552-qPCR-R TTGAACAGTGGCCAGGTAGAG 
Fggy-S-344-qPCR-F GCAAAATAGGAGTGATTGGGG 
Fggy-S-344-qPCR-R CACTGGATCTTTGCTGATCCC 
Fggy- S-387-qPCR-F ATCGTCCCTGGGTTCTGGTTG 
Fggy- S-387-qPCR-R CTGTAGGTTTCTGGCTGTGGC 
 
Reporter Assays 
Mouse myoblasts were plated in 12-well dishes at approximately 75,000 cells/well and allowed to 
proliferate overnight prior to transfection. Transfections were performed at 70-80% confluence 
using Turbofect Transfection Reagent (Thermo Scientific, Rockford, IL) and following the 
manufacturer's protocol. Cells were overlaid with 1 μg per well of total DNA, including 
250 ng/well of reporter plasmid, 125 ng/well of β -galactosidase (β-gal) as an internal control, and 
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empty pBluescript plasmid to a final concentration of 1 µg/well. The DNA had been allowed to 
complex with the transfection reagent for 20 minutes prior to cell overlay. After 24 hours, culture 
media was changed from 10% to 2% serum to induce differentiation. Media was harvested at 48 
h, 96 h, and 144 h post-media change to analyze secreted embryonic alkaline phosphatase (SEAP) 
levels. The Phospha-Light SEAP Reporter Gene Assay Kit (Life Technologies, Grand Island, NY) 
was used per the manufacturer’s instructions protocol to detect SEAP levels using a Biotec 
Synergy 2 microplate reader set for an endpoint read with a 2 s integration time to assess levels of 
luminescence. To adjust for variations in transfection efficiency between wells, β -gal activity was 
analyzed. Cells were lysed with Passive Lysis Buffer (Promega, Madison, WI) and homogenates 
cleared by centrifugation. Cell lysates were incubated with ortho-nitrophenyl-β-D-
galactopyranoside (ONPG) dissolved in Z Buffer (60 mM Na2HPO4·7H2O, 40 mM 
NaH2PO4·H2O, 10 mM KCl, 1 mM MgSO4, 50 mM β-mercaptoethanol, pH 7.0) overnight at 37 
°C. SEAP activity was divided by the β -gal activity to achieve corrected SEAP values.  
Reverse transcription quantitative PCR 
Reverse transcription quantitative PCR (RT-qPCR) was carried out using total RNA isolated from 
C2C12 cells and the iScript cDNA Synthesis Kit according to the manufacturer’s protocol (Bio‐ 
Rad, Hercules, CA). The reverse transcription of isolated RNA yielded complementary DNA 
(cDNA) that was then used for analysis of Fggy gene expression in C2C12 cells. Gene specific 
primers (Table 1) cDNA, and iTaq Universal SYBR Green Reaction Supermix were mixed 
according to the manufacturer’s instructions (Bio-Rad, Hercules, CA) and analyzed on the CFX 
Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA). The experiment was 
repeated as least two times and each condition was performed in biological triplicate, each 
individual biological replicate was used for cDNA amplification in duplicate, and each cDNA 
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amplification replicate was done in technical triplicates (three biological replicates × two cDNA 
synthesis replicates × three technical replicates = 18 individual reads per biological sample). The 
Fggy expression data was calculated after normalization to GAPDH expression using the 
2−ΔΔCt method. 
Protein purification and Western blot analysis 
Protein purification was achieved as previously described (Haddock et al., 2019, Hayes et al., 
2019, Lynch et al., 2019). Briefly, mouse myoblasts were cultured in 10 cm plates, harvested at 
various timepoints, and lysed for protein isolation. Fggy was exogenously expressed by 
transfection of cells with pcDNA3.1-Fggy expression plasmids after 24 hours of cell growth in 
10% FBS media using Turbofect transfection reagent according to the manufacturer’s instructions. 
Cells were then harvested at various timepoints of proliferation and differentiation and stored at 
−80 °C until cell lysis. Cells were lysed on ice in Universal Lysis Buffer (ULB)(+) (50 mM Tris, 
pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP-40, with addition of 1 mM PMSF, 1 mM DTT, 
10 mM β-glycerophosphate, 2 mM sodium molbydate and a protease inhibitor cocktail), cleared 
by centrifugation, and total protein concentration was determined using the Quick Start Bradford 
1X Dye Reagent and following the manufacturer’s instructions (Bio-Rad, Hercules, CA). 
Western blot procedures were conducted using 25-100 μg of protein run on a sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS PAGE) denaturing gel and transferred to 
polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Billerica, MA). To verify the quality 
of the transfer and equal protein loading, the membranes were stained using Ponceau S prior to 
blocking the membrane in 5% dry milk dissolved in Tris-buffered saline and 0.05% Tween-20 
(TTBS). The membranes were probed with anti-myosin heavy chain (MYH1/2/4/6), anti-
myogenin, anti-p-ERK, anti-ERK, anti-AKT-phospho-S473, anti-AKT, anti-GAPDH, and anti-α 
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tubulin primary antibodies and subsequently probed with a corresponding HRP-conjugated 
secondary (Table 2). Westerns were developed by incubating the membrane with ECL Western 
Blotting Substrate (Thermo Fisher Scientific, Waltham, MA) and imaged using the Amersham 
Imager 600 RGB system (GE Healthcare Life Sciences, Marlborough, MA). For the use of 
multiple antibodies on a single blot, membranes were striped with a 10% SDS, 0.5 M Tris-HCl pH 
6.8, β-mercaptoethanol solution, blocked again, and then probed and imaged as described 
previously. The intensity of the bands on the Western blots was quantified using the open access 
ImageJ software.  
Table 2. List of antibodies used in this study 
Antibody Source Catalog # Dilution 
anti-α-tubulin Santa Cruz Biotechnology, Dallas, TX sc-32293 WB: 1:1000 
anti-Myosin Heavy Chain 
(MYH1/2/4/6) 
Santa Cruz Biotechnology, Dallas, TX sc-32732 WB: 1:1000 
anti-myogenin Santa Cruz Biotechnology, Dallas, TX sc-12732 WB: 1:1000 
anti-GAPDH ProteinTech, Rosemont, IL 600041-lg WB: 1:5000 
anti-phospho-ERK Santa Cruz Biotechnology, Dallas, TX sc-7383 WB: 1:1000 
anti-ERK Santa Cruz Biotechnology, Dallas, TX sc-94 WB: 1:1000 
anti-Akt1-phospho-S473 ProteinTech, Rosemont, IL 66444-I-lg WB: 1:2000 
anti-Akt ProteinTech, Rosemont, IL 602032-lg WB: 1:5000 
Mouse anti-rabbit IgG-
HRP 
Santa Cruz Biotechnology, Dallas, TX sc-2357 WB: 1:5000 
Rabbit anti-mouse IgG-
HRP (H + L) 
Thermo Scientific, Rockford, IL PI31450 WB: 1:5000 
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Confocal fluorescent microscopy 
Mouse myoblast cells were plated on 3.5 cm glass bottom plates at a seeding density of 
approximately 100,000 cells/plate and transfected with 2.5 μg of pEGFP-Fggy expression 
plasmids at 70-80% confluency. Cells were fixed at 48h post-plating with 4% paraformaldehyde 
dissolved in 0.1 M NaCacodylate and DRAQ5 nuclear stain was used to visualize cell nuclei 
(ThermoFisher Scientific, Waltham, MA). Imaging was conducted on an Olympus Fluoview FV-
1000 confocal fluorescent microscope with a Super Apochromat UPLSAPO 20X objective or a 
Super Apochromat UPLSAPO 60×W objective. The GFP and DRAQ5 images were then merged 
using the open access ImageJ software and utilizing the Open Microscopy Environment Bio-
Formats software plugin tool. 
Statistics  
The data are presented as the mean ± standard deviation (±SD). Statistical analysis was conducted 
using a two-tailed t-test and a P value ≤ 0.05 was considered significant.  
 
Results  
Fggy is induced during skeletal muscle atrophy  
To identify genes that are differentially expressed in response to neurogenic atrophy, RNA was 
harvested from the triceps surae (TS) muscle of mice following 3 and 14 days of denervation as 
previously described (Furlow et al., 2013). A significant number of genes that have not previously 
been studied in skeletal muscle were shown to be differentially expressed in response to 
neurogenic skeletal muscle atrophy, including Fggy carbohydrate kinase domain containing 
(Fggy). At 3-days post denervation, Fggy showed a small but significant increase in expression 
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compared to control muscles while at 14-days post denervation, the increase in Fggy expression 
was greater compared to the control muscles (Fig. 8).  
 
Figure 8. Fggy is induced in response to denervation-induced skeletal muscle atrophy. Whole 
genome expression analysis was conducted on triceps surae muscle from wild-type (WT) mice 
after 3 days (3D) and 14 days (14D) of denervation (DEN). Each condition represents the average 
expression from three animals and error bars represent ± SD. White bars represent the controls and 
gray bars represent DEN. Significant difference between denervated mice and control mice in the 
same group, P < 0.05. Fggy-L was recognized by a probe on exon 16 and expression showed a 
significant increase in atrophic conditions at 3D and 14D post denervation.  
 
Fggy-L and Fggy-S are alternatively spliced in muscle cells 
Fggy has been shown to be most abundantly expressed in liver but is also found to be expressed 
in skeletal muscle (Fagerberg et al., 2014), which is not unexpected considering this gene may 
play a role in carbohydrate metabolism. This study is the first to identify four alternative Fggy 
isoforms simultaneously expressed in muscle cells, two of which are completely novel (Fig. 9A-
B). We have designated these four isoforms as Fggy-Long form, which consists of 552 amino acids 
(Fggy-L-552), an alternative Fggy-Long form consisting of 482 amino acids (Fggy-L-482), Fggy-
Short form consisting of 387 amino acids (Fggy-S-387), and an alternative Fggy-Short form 




than their previously identified counterparts with Fggy-L-482 lacking exons 10 and 11 and Fggy-
S-344 lacking exon 7 (Fig. 9A-B). The Fggy-S-387 isoform differs from the Fggy-L-552 isoform 
at amino acids 360 to 387 and is lacking amino acids 388-552. Bioinformatic analysis of the Fggy 
gene in both humans and rodents revealed a locus that generates numerous splice variants and has 
8 putative protein encoding isoforms in mice that result from alternative splicing and/or alternative 
transcription initiation sites. Of the 8 putative protein encoding transcripts of the murine Fggy 
gene, 2 have been added to the CCDS database. The first isoform we have designated as Fggy-L-
552 (CCDS51233), which consists of 16 exons and 15 introns and has a predicted molecular weight 
of approximately 60 kDa. The second isoform we have designated as Fggy-S-387 (CCDS18365), 
which consists of 11 exons and 10 introns and produces a protein with a predicted molecular weight 
of approximately 42.5 kDa. Interestingly, both isoforms retain the conserved FGGY-N and FGGY-





Figure 9. Schematics of alternative transcripts of Fggy-L and Fggy-S. (A) Fggy-L-552 has 16 
exons and 15 introns and an alternative transcript without exons 10 and 11 (red circle) named 
Fggy-L-482 for the number of amino acids in the protein sequence. The schematic of the Fggy 
genes structure was downloaded from the Ensembl database (www.ensembl.org). (B) Fggy-S-387 
has 11 exons and 10 introns and an alternative transcript without exon 7 (red circle) named Fggy-
S-344. The schematic of the Fggy genes structure was downloaded from the Ensembl database 
(www.ensembl.org).  
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Fggy-L is upregulated during muscle cell differentiation 
To analyze the expression profile of Fggy in proliferating myoblasts and differentiated myotubes, 
qPCR primers were designed distinguish between the four alternative splice variants. C2C12 cells 
were harvested at proliferation day 2 (PD2), differentiation day 2 (DD2), and differentiation day 
7 (DD7). RNA was isolated and used for analysis of Fggy expression by reverse transcription 
quantitative polymerase chain reaction (RT-qPCR). The results show that the expression of the 
Fggy-L isoforms peak during early differentiation (Fig. 10A-B), while the expression of the Fggy-
S isoforms remains relatively constant between proliferation and differentiation (Fig. 10C-D).  
 
 
Figure 10. Expression pattern analysis of the Fggy isoforms in cultured muscle cells. RT-
qPCR analysis of the (A) Fggy-L-552, (B) Fggy-L-487, (C) Fggy-S-384, and (D) Fggy-S-344 
transcripts in proliferating (PD2) myoblasts and early (DD2) and late differentiated (DD7) 











Fggy localizes to the cytoplasm of myoblasts 
To elucidate the sub-cellular location of Fggy in muscle cells, pEGFP-Fggy-L and pEGFP-Fggy-
S expression plasmids were created and transfected into C2C12 cells. The Fggy-L isoforms both 
show a diffuse and uniform cytoplasmic localization pattern (Fig. 11), while the Fggy-S isoforms 
show a more punctate cytoplasmic localization pattern (Fig. 12) These distinct localization patterns 
may be due to the Fggy-L isoforms possessing a 165 amino acid c-terminal tail region that is 
missing in the Fggy-S isoforms (Fig. 13).  
 
 
Figure 11. Fggy-L isoforms localize to the cytoplasm in C2C12 cells. C2C12 cells that were 
transfected with pEGFP-Fggy-L expression plasmids and imaged at 60X. Fggy-L-552 (Panels 1-
3) and Fggy-L-482 (Panels 4-6) were found to localize to the cytoplasm of myoblasts. Nuclei were 




Figure 12. Fggy-S isoforms localize to the cytoplasm in a punctate pattern in C2C12 cells. 
C2C12 cells that were transfected with pEGFP-Fggy-S expression plasmids and imaged at 60X. 
Fggy-S-387 (Panels 1-3) and Fggy-S-344 (Panels 4-6) were found to localize in a punctate pattern 




Figure 13. Alignment of the Fggy protein sequences. The amino acid sequences of the four 
murine Fggy isoforms aligned using the ClustalW2 algorithm and shaded using Boxshade.  
 
 
Ectopic Fggy expression attenuates muscle cell differentiation  
To determine the effect of Fggy overexpression on muscle cell differentiation, the pcDNA3-Fggy-
L-552 and pcDNA3-Fggy-S-387 expression plasmids were used to transfect C2C12 cells. The cells 
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were then harvested over a differentiation time course, lysed, and protein homogenates were used 
for Western blot analysis of known markers of muscle cell differentiation. Myosin heavy chain 
(MyHC) and myogenin both showed significantly blunted expression in response to ectopic 
expression of Fggy-L-552 and Fggy-S-387 at all differentiation timepoints (Fig. 14A and 15A). 
To confirm Fggy-mediated inhibition of muscle cell differentiation, biological quadruplicates of 
Fggy-L-552 or Fggy-S-387 overexpressing cells were harvested at differentiation day 2 and 
analyzed by Western blot (Fig. 14B and 15B). Quantification of the Western blots for MyHC and 
myogenin protein levels confirmed a statistically significant reduction in both (Fig. 14C and 15C). 






Figure 14. Ectopic expression of Fggy-L attenuates muscle cell differentiation. C2C12 cells 
were transfected with the pcDNA-Fggy-L-552 expression plasmid. Cells were maintained in 10% 
serum media for the proliferation timepoints and switched to 2% serum media to induce 
differentiation. Cells were harvested at proliferation day 2 (PD2) and differentiation days 1, 3, and 
5 (DD1, DD3, DD5). (A) Western blot analysis of the differentiation markers Myosin Heavy Chain 
(MyHC) and myogenin showed significantly lower levels of expression at DD3 and DD5 in 
response to Fggy-L-552 overexpression. (B) C2C12 cells were transfected with the pcDNA-Fggy-
L-552 expression plasmid in biological quadruplicates, maintained in proliferation media, and then 
switched to differentiation media (2% serum) for 2 days. Western blot analysis of MyHC and 
myogenin using protein homogenates from C2C12 cells differentiated for 2 days. (C) Quantification 
of the Western blot band intensities from part B. Relative intensity of each band was corrected to 
the GAPDH band intensity for each corresponding biological replicate. Significant differences 





Figure 15. Ectopic Fggy-S expression attenuates muscle cell differentiation. C2C12 cells were 
transfected with the pcDNA-Fggy-S-387 expression plasmid. Cells were maintained in 10% serum 
media for the proliferation timepoints and switched to 2% serum media to induce differentiation. 
Cells were harvested at proliferation day 2 (PD2) and differentiation days 1, 3, and 5 (DD1, DD3, 
DD5). (A) Western blot analysis of the differentiation markers Myosin Heavy Chain (MyHC) and 
myogenin showed significantly lower levels of expression at DD3 and DD5 in response to Fggy-
S-387 overexpression. (B) C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression 
plasmid in biological quadruplicates, maintained in proliferation media, and then switched to 
differentiation media (2% serum) for 2 days. Western blot analysis of MyHC and myogenin using 
protein homogenates from C2C12 cells differentiated for 2 days. (C) Quantification of the Western 
blot band intensities from part B. Relative intensity of each band was corrected to the GAPDH 
band intensity for each corresponding biological replicate. Significant differences between control 






Fggy overexpression inhibits MAPK signaling 
To evaluate the impact of Fggy overexpression on pathways critical for muscle cell differentiation, 
Fggy-L-552, Fggy-L-482, Fggy-S-387, and Fggy-S-344 were overexpressed individually in C2C12 
cells along with an activator protein-1 (AP-1) reporter gene plasmid. As one of the terminal targets 
of the MAPK signaling pathway, AP-1 activity can be used to measure the activity of the MAPK 
signaling pathway. Culture media was harvested, and SEAP activity was measured, revealing that 
all four Fggy isoforms inhibited MAPK signaling (Fig. 16). Phosphorylation levels of ERK1/2 
were then analyzed via western blot. Phosphorylated ERK1/2 (p-ERK1/2) levels were found to be 
lower in cells ectopically expressing Fggy-L-552 (Fig. 17A) or Fggy-S-387 (Fig. 18A). To confirm 
inhibition of ERK1/2 phosphorylation levels, biological quadruplicates of Fggy-L-552 or Fggy-S-
387 overexpressing cells were harvested at differentiation day 2 and analyzed by Western blot 
(Fig. 17B and 18B). Quantification of the Western blots for ERK1/2 protein and p-ERK1/2 levels 
confirmed a statistically significant reduction in phosphorylated ERK1/2 (Fig. 17C and 18C). 
 
Figure 16. Ectopic expression of Fggy inhibits MAPK signaling. C2C12 cells were transfected 
with pcDNA3-Fggy-L-552, pcDNA3-Fggy-L-482, pcDNA3-Fggy-S-387, or pcDNA3-Fggy-S-
344 expression plasmids along with a MAP kinase signaling pathway reporter gene. SEAP activity 
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was measured by harvesting culture media 72 hours post-media change. Cells ectopically 




Figure 17. Ectopic expression of Fggy-L inhibits the ERK1/2 branch of the MAPK signaling 
cascade. C2C12 cells were transfected with the pcDNA-Fggy-L-552 expression plasmid. Cells were 
maintained in 10% serum media for the proliferation timepoints and switched to 2% serum media 
to induce differentiation. Cells were harvested at proliferation day 2 (PD2) and differentiation days 
1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis of ERK1/2 and phospho-ERK1/2 showed 
significantly lower levels at all time points in response to Fggy-L-552 overexpression. (B) C2C12 
cells were transfected with the pcDNA-Fggy-L-552 expression plasmid in biological 
quadruplicates, maintained in proliferation media, and then switched to differentiation media (2% 
serum) for 2 days. Western blot analysis of ERK1/2 and phosphor-ERK1/2 using protein 
homogenates from C2C12 cells differentiated for 2 days. (C) Quantification of the Western blot 
band intensities from part B. Relative intensity of each band was corrected to the GAPDH band 
intensity for each corresponding biological replicate. Significant differences between control cells 





Figure 18. Ectopic expression of Fggy-S inhibits the ERK1/2 branch of the MAPK signaling 
cascade. C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression plasmid. Cells were 
maintained in 10% serum media for the proliferation timepoints and switched to 2% serum media 
to induce differentiation. Cells were harvested at proliferation day 2 (PD2) and differentiation days 
1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis of ERK1/2 and phospho-ERK1/2 showed 
significantly lower levels at all time points except DD3 in response to Fggy-S-387 overexpression. 
(B) C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression plasmid in biological 
quadruplicates, maintained in proliferation media, and then switched to differentiation media (2% 
serum) for 2 days. Western blot analysis of ERK1/2 and phosphor-ERK1/2 using protein 
homogenates from C2C12 cells differentiated for 2 days. (C) Quantification of the Western blot 
band intensities from part B. Relative intensity of each band was corrected to the GAPDH band 
intensity for each corresponding biological replicate. Significant differences between control cells 
compared to cells ectopically expressing Fggy-L-552, (*: P < 0.05, ns = no significance).  
 
 
Overexpression of Fggy destabilizes AKT 
In addition to the MAPK signaling pathway, AKT has been found to modulate muscle cellular 
differentiation (Coleman et al., 1995). In response to Fggy-L-552 and Fggy-S-387 overexpression, 
AKT protein and phosphorylation levels were found to be significantly lower over a differentiation 
time course (Fig. 19A and 20A). To confirm AKT destabilization and inhibition of AKT 
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phosphorylation levels, biological quadruplicates of Fggy-L-552 or Fggy-S-387 overexpressing 
cells were harvested at differentiation day 2 and analyzed by Western blot (Fig. 19B and 20B). 
Quantification of the Western blots for AKT protein and p-AKT levels confirmed a statistically 
significant reduction in both AKT protein levels and phosphorylated AKT (Fig. 19C and 20C). 
 
 
Figure 19. Ectopic expression of Fggy-L destabilizes AKT in muscle cells. C2C12 cells were 
transfected with the pcDNA-Fggy-L-552 expression plasmid and harvested at proliferation day 2 
(PD2) and differentiation days 1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis showed 
reduced levels of phosphorylated AKT with Fggy over expression at all timepoints. (B) C2C12 cells 
were transfected with the pcDNA-Fggy-L-552 expression plasmid in biological quadruplicates, 
maintained in proliferation media, and then switched to differentiation media (2% serum) for 2 
days. Western blot analysis of p-AKT and AKT using protein homogenates from C2C12 cells 
differentiated for 2 days. (C) Quantification of the Western blot band intensities from part B. 
Relative intensity of each band was corrected to the GAPDH band intensity for each corresponding 
biological replicate. Significant differences between control cells compared to cells ectopically 






Figure 20. Ectopic expression of Fggy-S destabilizes AKT in muscle cells. C2C12 cells were 
transfected with the pcDNA3-Fggy-S-387 expression plasmid and harvested at proliferation day 2 
(PD2) and differentiation days 1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis showed 
lower levels of phosphorylated AKT with Fggy overexpression at all timepoints except DD5. (B) 
C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression plasmid in biological 
quadruplicates, maintained in proliferation media, and then switched to differentiation media (2% 
serum) for 2 days. Western blot analysis of p-AKT and AKT using protein homogenates from 
C2C12 cells differentiated for 2 days. (C) Quantification of the Western blot band intensities from 
part B. Relative intensity of each band was corrected to the GAPDH band intensity for each 
corresponding biological replicate. Significant differences between control cells compared to cells 










Fggy may regulate muscle cell differentiation through modulation of the MAPK pathway 
The levels of Fggy-L transcript were highest during differentiation, leading us to investigate the 
effect of ectopic expression of Fggy on the induction of MyHC and myogenin during muscle cell 
differentiation. In this study, we found that Fggy overexpression resulted in the inhibition of both 
MyHC and myogenin expression, suggesting attenuation of muscle cell differentiation. Although 
this data provides evidence that Fggy may play a role in proper muscle cell differentiation, it also 
suggests a more complex interaction with myogenin, since myogenin expression also increases in 
response to skeletal muscle atrophy induced by denervation (Moresi et al., 2010, Furlow et al., 
2013). The mechanism by which Fggy inhibits muscle differentiation remains to be fully 
elucidated; however, we did find that overexpression of any of the Fggy isoforms was sufficient 
to inhibit the MAPK signaling pathway. It has previously been shown that MAP kinase signaling 
is necessary for the proper differentiation of myotubes (Cooper et al., 1982) and may occur through 
any of four distinct branches, including the extracellular signal-related kinase 1/2 (ERK1/2), p38, 
c-Jun N-terminal kinase (JNK), or ERK5 (Cargnello and Roux, 2011). Therefore, we wanted to 
determine which of these branches might be regulated by Fggy and, based on previous studies 
from our lab, we hypothesized that Fggy may target the ERK1/2 branch in muscle cells (Haddock 
et all, 2019, Hayes et al., 2019, Cooper et al., 2020, Labuzan et al., 2020). Western blot analysis 
showed that Fggy overexpression in C2C12 cells decreased phosphorylation of ERK1/2 and 
inhibited an AP-1 reporter gene. The ERK1/2 branch varies in activity during the progression from 
myoblast to myotube and finally to myotube fusion. ERK1/2 phosphorylation is highest during 
proliferation and late differentiation and plays a role in both the initiation of myogenesis and 
myotube fusion (Bennett and Tonks, 1997). The results from this current study, showing that 
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overexpression of Fggy may attenuate the MAPK pathway, suggest a possible mechanism by 
which Fggy functions in regulating muscle cell differentiation. 
Fggy may contribute to protein degradation through AKT inhibition 
The AKT pathway is also involved in muscle cell differentiation and Fggy overexpression was 
shown to decrease protein and phosphorylation levels of AKT. Interestingly, a previous study 
found that elevated levels of Fggy expression in adipose tissue were positively correlated with 
obesity in male mice exposed to low doses of BPA (Taylor et al., 2018). Due to their coordinated 
role in energy metabolism, the relationship between adipose tissue and skeletal muscle is well 
established if not fully understood. Indeed, a recent study showed that transplantation of adipose 
tissue from mice that regularly trained on a running wheel into sedentary mice resulted in improved 
insulin-stimulated glucose uptake in the skeletal muscle of the sedentary mice (Stanford et al., 
2015). Insulin induced AKT signaling modulates adipose tissue metabolism by increasing cellular 
glucose uptake, protein synthesis, and synthesis of new fatty acids (Zhang and Liu, 2014). The 
involvement of AKT in lipid and glucose metabolism provides a possible method by which Fggy 
may participate in the regulation of fat deposition. Taylor et al. found evidence of a positive 
relationship between Fggy expression and levels of adipose tissue, while our data showed that 
increased Fggy expression decreases AKT expression. While these findings, might seem 
contradictory as the activation of AKT leads to the synthesis of new fatty acids, Fggy may have a 
muscle specific function that differs from its role in adipose tissue. In 2019 it was found that obese 
adipose tissue accelerated denervation-induced muscle atrophy through FoxO activation and an 
increased expression of FoxO target genes associated with atrophy (Zhu et al, 2019). This data 
also supports the hypothesis that induction of Fggy during muscle atrophy may lead to the negative 
regulation of AKT signaling and block AKT-mediated inhibition of the transcriptional activation 
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of atrophy-promoting genes, including MuRF1 and MAFbx. The activation of these genes may 
then lead to protein degradation, muscle wasting, and weakness, further suggesting that the 
increase in Fggy expression in response to denervation may contribute to muscle wasting    
 
Future Directions 
Characterize the regulation of Fggy splice variant expression in muscle cells 
The identification and characterization of Fggy in skeletal muscle expands our understanding of 
the molecular mechanisms of skeletal muscle atrophy. In this study, we found that the Fggy gene 
produces two novel transcripts in skeletal muscle in addition to two transcripts that have previously 
been validated. The expression of these novel transcripts in skeletal muscle suggests that Fggy 
may have a muscle specific function. The levels of the two Fggy-L transcripts were found to be 
increased during differentiation, while the two Fggy-S transcripts did not change significantly 
between proliferation and differentiation. Proper muscle cell differentiation is regulated by the 
expression of myogenic regulatory factors (MRF’s), with MyoD and Myogenin found to be most 
active during early myoblast differentiation (Bentzinger et al., 2012). MRF’s function by binding 
to a DNA sequence, called an E-box, with their conserved helix-loop-helix domain. These binding 
sequences are often found in the promoter regions of muscle-specific genes (Berkes and Tapscott, 
2005). Both MyoD and myogenin have also been shown to increase in expression during 
neurogenic skeletal muscle atrophy (Merlie et al., 1994). The upregulated expression of the Fggy 
gene in skeletal muscle during early differentiation and during neurogenic skeletal muscle atrophy 
suggests that the increase in MyoD or myogenin may participate in the upregulation of Fggy 
expression during muscle atrophy. Moreover, future investigation of the differential splicing of 
Fggy during muscle cell development could determine if expression of specific MRF’s promotes 
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expression of one isoform over another during muscle cell growth and differentiation. A better 
understanding of the regulation of Fggy in muscle will help to improve our knowledge of the 
functions that the different isoforms of Fggy play in muscle development and atrophy. 
Fggy may function within the pentose phosphate pathway 
The pentose phosphate pathway, also known as the phosphogluconcate pathway, generates 
NADPH and molecules necessary for nucleotide synthesis (Alfarouk et al., 2020). While the liver 
is found to have one of the highest levels of PPP activity (Heinrich et al., 1976), denervation-
induced skeletal muscle atrophy causes an increase in levels of PPP activity specifically in muscle 
cells (Wagner et al., 1977). This study linked the regeneration of skeletal muscle with enzymatic 
activity of the PPP using a myotoxic local anesthetic called Marcaine that promotes rapid 
regeneration of muscle tissue (Benoit and Belt, 1970). In humans, Fggy has been found to be 
expressed highest in the liver (Fagerberg et al., 2014). This correlates with a previous study that 
found Fggy may function as a D-ribulokinase in HEK293 cells, suggesting that the role of this 
enzyme may be to phosphorylate free D-ribulose to prevent toxic accumulation (Singh et al., 
2017), as free D-ribulose is not found to be abundant in mammalian cells but is found in human 
and rat urine (Futterman and Roe, 1955). It was also found that YDR109C, the yeast homolog of 
Fggy, showed a substrate preference to D-ribulose (Singh et al., 2017). Interestingly, the Molecular 
INTeraction (MINT) data base provides evidence of an interaction between Fggy and 6-
phosphogluconolactonase (Pgls) which, along with D-ribulose, has been identified as a component 
of the pentose phosphate pathway (PPP). In the context of skeletal muscle atrophy, the previous 
data suggests Fggy may play a role in the pentose phosphate pathway as the body attempts to 
regenerate atrophied muscle tissue. As the PPP activity increases in muscle, the need to 
phosphorylate D-ribulose for use in this pathway also increases, which could account for the 
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increase in Fggy expression. This potential role for Fggy in skeletal muscle could be investigated 
through the mutagenesis of regions predicted to interact with D-ribulose based on structural 
homology models of the yeast Ydr109c and human FGGY proteins. It would be possible to 
compare the amount of free ribulose in C2C12 cells in response to ectopic expression of wild-type 
and mutant Fggy, as well as, in response to Fggy expression knockdown. These studies could 
determine if C2C12 cells contain enough free ribulose to be detected and if there are changes in 
those levels in response to an increase or decrease in Fggy expression, as well as, if the kinase 
activity of Fggy is necessary for ribulose phosphorylation. As it has not yet been determined which 
mutation will result in a kinase dead Fggy protein, multiple mutations would have to be tested and 
the amount of free ribulose measured in order to show the loss of activity. This could be done by 
site-directed mutagenesis of conserved amino acids identified in 12 organisms across different 
kingdoms of life (Fig. 21) (Singh et al, 2017) or through truncating the Fggy gene until a change 
in activity is achieved, such as deletion of either the Fggy-N or Fggy-C functional domains which 




Figure 21. Alignment of D-ribulokinase protein sequences across different kingdoms of 
life. Conserved amino acids are highlighted in increasingly darker shades of blue relative to a 
higher degree of conservation. The top 20 specificity determining positions (SDPs) are highlighted 
in red. The amino acids that are predicted to interact with the pentose substrate are highlighted 
in yellow. This is based on structural homology models of the yeast Ydr109c and human FGGY 




Figure 22. Model of the human Fggy protein. Shown in complex with the ligand d-xylulose 
(light green color). The Fggy-C domain is highlighted in dark blue and Fggy-N domain is 
highlighted in pink (Singh et al., 2017). 
 
Fggy may interact with deubiquitinases  
Although Fggy was found to be correlated with instances of sporadic amyotrophic lateral sclerosis 
(S-ALS) (Dunckley et al., 2007), multiple other studies found no evidence to support this finding 
(Daoud et al., 2012 and Cai et al., 2014). Interestingly, Fggy has been predicted to interact with 
two deubiquitinases, Myb-like, SWIRM, and MPN domains-containing protein 1 (MYSMP1) and 
Ubiquitin-specific protease 24 (USP24) (Jensen et al., 2008). MYSMP1 has been shown to act as 
a transcriptional activator by releasing the inhibition caused by ubiquitination of histone 2A (H2A) 
(Zhu et al., 2007). In addition, USP24 has been implicated in apoptosis and iron metabolism 
responsible for avoiding cell death (Sun et al., 2018). USP24 has also been found to deubiquitinate 
p53, which is necessary for the stabilization of p53 expression (Zhang et al., 2015). This is 
interesting as USP24 is found to decrease 7 days after denervation in gastrocnemius muscle tissue 
(Lang et al., 2017), while p53 is found to increase in expression 7 days after denervation in tibialis 
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anterior muscle (Stouth et al., 2020). Skeletal muscle atrophy has been shown to cause an increase 
in the expression of various deubiquitinases, which is thought to compensate for the increased 
demand for ubiquitin that is needed to target proteins for degradation by the proteasome (Wing, 
2013). Moreover, the removal of ubiquitin tags from some substrates may also disrupt normal 
protein-protein interactions and complex formation and allow for ubiquitination of complexed 
proteins by E3 ligases eventually leading to their destruction by the proteasome. Further 
investigation into possible interactions between Fggy and USP24 and MYSMP1 through co-
immunoprecipitation assays will provide a more complete understanding of the functional role of 
Fggy in the molecular mechanisms of skeletal muscle atrophy. The finding that Fggy shows 
increased expression under neurogenic atrophy inducing conditions is just one step to 
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